Epoetin dosing and dialysis facility ownership [5]

JAMA

Volumn 298, Issue 8, 2007, Pages 861-862

  Kliger, Alan S ^a   Nissenson, Allen R ^b  

^a HOSPITAL OF SAINT RAPHAEL   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ERYTHROPOIETIN; HEMOGLOBIN; RECOMBINANT ERYTHROPOIETIN; ANTIANEMIC AGENT;

ANEMIA; CHRONIC KIDNEY DISEASE; DIALYSIS; EVIDENCE BASED PRACTICE; HEALTH CARE; HEALTH CARE FACILITY; HEALTH CARE POLICY; HEMATOCRIT; HUMAN; LETTER; MEDICARE; NEPHROLOGIST; OBSERVATIONAL STUDY; PRACTICE GUIDELINE; PRESCRIPTION; PRIORITY JOURNAL; REIMBURSEMENT; RENAL REPLACEMENT THERAPY; RISK BENEFIT ANALYSIS; DRUG UTILIZATION; NOTE; ORGANIZATION AND MANAGEMENT; OUTPATIENT DEPARTMENT; PATIENT CARE; STANDARD; STATISTICS; UNITED STATES;

AMBULATORY CARE FACILITIES; ANEMIA; DRUG UTILIZATION; EPOETIN ALFA; HEMATINICS; HUMANS; OWNERSHIP; PATIENT CARE TEAM; RENAL DIALYSIS; UNITED STATES;

EID: 34548056693     PISSN: 00987484     EISSN: 15383598     Source Type: Journal    
DOI: 10.1001/jama.298.8.861     Document Type: Letter

References (3)

1. Thamer M, Zhang Y, Kaufman J, Cotter D, Dong F, Hernan MA. Dialysis facility ownership and epoetin dosing in patients receiving hemodialysis. JAMA. 2007;297(15):1667-1674.
2. Coyne DW. Use of epoetin in chronic renal failure. JAMA. 2007;297(15):1713-1716.
3. Collins AJ, Brenner RM, Ofman JJ, et al. Epoetin alfa use in patients with ESRD: an analysis of recent US prescribing patterns and hemoglobin outcomes. Am J Kidney Dis. 2005;46(3):481-488.